Effect of various doses of rosuvastatin in the treatment of elderly patients with unstable angina pectoris.

OBJECTIVES

This prospective study aimed to explore the effects of various doses of rosuvastatin on the hemodynamic changes, highly sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) levels in elderly patients with unstable angina pectoris.

METHODS

One-hundred and six elderly patients with unstable angina pectoris were enrolled and divided into group A (n=55) and group B (n=51). Under the same treatment for angina pectoris, patients in groups A and B were administered with 5 mg and 10 mg of rosuvastatin orally once every night, respectively. The two groups were compared in terms of hemorheology, coagulation indices and immune reaction (serum hs-CRP and IL-6 levels), changes of clinical indices, electrocardiograph (ECG), therapeutic effect, and incidence of adverse reactions. Serum hs-CRP and IL-6 levels were detected by ELISA method, and their correlation was analyzed by Pearson method.

RESULTS

Whole blood viscosity at high cut (BVH), whole blood viscosity at low cut (BVL), plasma viscosity (PV), and erythrocyte sedimentation rate (ESR), immunoglobulin index, and the hs-CRP and IL-6 levels decreased in both groups after treatment and were lower in group B than in group A (<0.05). Prothrombin time (PT) and activated partial thromboplastin time (APTT) increased, while fibrinogen (FIB) decreased in both groups after treatment (<0.05). Group B was superior to group A in the onset times of myocardial ischemia and angina pectoris, the total duration of myocardial ischemia, and the total effective rate indicated by ECG (<0.05). No statistical difference was observed in the incidence of adverse reactions between the two groups after treatment (>0.05).

CONCLUSIONS

The optimal efficacy of rosuvastatin at 10 mg/day was higher than that of rosuvastatin at 5 mg/day.